ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	747.4	614.38	486.82	316.39	216.14	208.48
Revenue Growth (YoY)	38.68%	26.20%	53.87%	46.38%	3.67%	0.93%
Cost of Revenue	291.01	250.21	181.51	138.79	100.61	87.16
Gross Profit	456.39	364.17	305.3	177.6	115.53	121.32
Selling, General & Admin	298.19	237.24	161.7	124.04	84.29	64.99
Research & Development	53.87	44.58	34.29	22.32	11.37	16
Other Operating Expenses	-	-	-	-	0.78	11.26
Operating Expenses	436.59	349.55	255.77	203.33	143.7	136.89
Operating Income	19.81	14.62	49.53	-25.73	-28.17	-15.57
Interest Expense	-31.4	-33.14	-35.05	-28.42	-11.95	-9.48
Interest & Investment Income	12.13	15.53	8.11	0.37	0.02	0.03
Other Non Operating Income (Expenses)	-1.98	-4.03	-0.16	0.67	-4.71	-0.49
EBT Excluding Unusual Items	-1.44	-7.02	22.43	-53.12	-44.8	-25.52
Merger & Restructuring Charges	-8.9	-12.4	-1.13	-5.68	-	-
Gain (Loss) on Sale of Investments	-1.23	6.31	-	-	-	-
Gain (Loss) on Sale of Assets	-	5.35	-	-	1.82	-
Asset Writedown	-7.6	-7.6	-	-0.11	-2.37	-0.45
Legal Settlements	-	-	-	-	-8.75	-
Other Unusual Items	4.42	-6.85	-1.43	-3.76	-1.96	-
Pretax Income	-14.75	-22.21	19.87	-62.67	-56.06	-25.96
Income Tax Expense	-4.54	-3.69	1.09	-14.77	-13.46	-3.41
Net Income	-10.21	-18.52	18.78	-47.9	-42.6	-22.55
Preferred Dividends & Other Adjustments	2.49	1.63	3.3	1.63	0.19	-
Net Income to Common	-12.71	-20.15	15.48	-49.52	-42.79	-22.55
Shares Outstanding (Basic)	20	19	18	16	13	12
Shares Outstanding (Diluted)	20	19	18	16	13	12
Shares Change (YoY)	0.97%	6.18%	11.89%	29.09%	5.28%	-0.63%
EPS (Basic)	-0.65	-1.04	0.86	-3.05	-3.40	-1.88
EPS (Diluted)	-0.65	-1.04	0.85	-3.05	-3.40	-1.88
Free Cash Flow	125.44	47.78	110.09	-40.08	0.77	9.13
Free Cash Flow Per Share	6.41	2.47	6.05	-2.46	0.06	0.76
Gross Margin	61.06%	59.27%	62.71%	56.13%	53.45%	58.19%
Operating Margin	2.65%	2.38%	10.17%	-8.13%	-13.03%	-7.47%
Profit Margin	-1.70%	-3.28%	3.18%	-15.65%	-19.80%	-10.82%
Free Cash Flow Margin	16.78%	7.78%	22.61%	-12.67%	0.35%	4.38%
EBITDA	104.33	82.35	109.32	33.92	19.08	29.07
EBITDA Margin	13.96%	13.40%	22.46%	10.72%	8.83%	13.94%
D&A For EBITDA	84.52	67.73	59.79	59.65	47.25	44.64
EBIT	19.81	14.62	49.53	-25.73	-28.17	-15.57
EBIT Margin	2.65%	2.38%	10.17%	-8.13%	-13.03%	-7.47%
Effective Tax Rate	-	-	5.50%	-	-	-

Updated Aug 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q